The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...

Pharmaceutical professionals expect digital solutions to solve drug development headaches, with AI already proving disruptive ...

The EC has granted approval to Novartis' Kisqali (ribociclib) plus an aromatase inhibitor to treat early breast cancer ...